1. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021;160:1570-1583.
2. Takenaka K, Ohtsuka K, Kitazume Y, et al. Utility of magnetic resonance enterography for small bowel endoscopic healing in patients with Crohn’s disease. Am J Gastroenterol 2018;113:283-294.
3. Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 2017;390:2779-2789.
6. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s Disease Activity Index and endoscopic findings. Inflamm Bowel Dis 2008;14:40-46.
8. Mooiweer E, Fidder HH, Siersema PD, Laheij RJ, Oldenburg B. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation. Inflamm Bowel Dis 2014;20:307-314.
9. Inokuchi T, Kato J, Hiraoka S, et al. Fecal immunochemical test versus fecal calprotectin for prediction of mucosal healing in Crohn’s disease. Inflamm Bowel Dis 2016;22:1078-1085.
10. Serada S, Fujimoto M, Terabe F, et al. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm Bowel Dis 2012;18:2169-2179.
11. Takenaka K, Kitazume Y, Kawamoto A, et al. Serum leucine-rich α2 glycoprotein: a novel biomarker for transmural inflammation in Crohn’s disease. Am J Gastroenterol 2023;118:1028-1035.
12. Kawamoto A, Takenaka K, Hibiya S, Ohtsuka K, Okamoto R, Watanabe M. Serum leucine-rich α2 glycoprotein: a novel biomarker for small bowel mucosal activity in Crohn’s disease. Clin Gastroenterol Hepatol 2022;20:e1196-e1200.
16. Zubin G, Peter L. Predicting endoscopic Crohn’s disease activity before and after induction therapy in children: a comprehensive assessment of PCDAI, CRP, and fecal calprotectin. Inflamm Bowel Dis 2015;21:1386-1391.
19. Takenaka K, Ohtsuka K, Kitazume Y, et al. Comparison of magnetic resonance and balloon enteroscopic examination of the small intestine in patients with Crohn’s disease. Gastroenterology 2014;147:334-342.
20. Takenaka K, Ohtsuka K, Kitazume Y, et al. Correlation of the endoscopic and magnetic resonance scoring systems in the deep small intestine in Crohn’s disease. Inflamm Bowel Dis 2015;21:1832-1838.
21. Ordás I, Rimola J, Alfaro I, et al. Development and validation of a simplified magnetic resonance index of activity for Crohn’s disease. Gastroenterology 2019;157:432-439.
22. Takenaka K, Fujii T, Suzuki K, et al. Small bowel healing detected by endoscopy in patients with Crohn’s disease after treatment with antibodies against tumor necrosis factor. Clin Gastroenterol Hepatol 2020;18:1545-1552.
23. Naka T, Fujimoto M. LRG is a novel inflammatory marker clinically useful for the evaluation of disease activity in rheumatoid arthritis and inflammatory bowel disease. Immunol Med 2018;41:62-67.